As per MRFR analysis, the U.S. Genetic Testing Market Size was estimated at 2.74 (USD Billion) in 2023.The U.S. Genetic Testing Market Industry is expected to grow from 3.68(USD Billion) in 2024 to 16.25 (USD Billion) by 2035. The U.S. Genetic Testing Market CAGR (growth rate) is expected to be around 14.456% during the forecast period (2025 - 2035)
Key US Genetic Testing Market Trends Highlighted
The U.S. Genetic Testing Market is experiencing several significant trends driven by various factors. One of the key market drivers is the increasing awareness of personalized medicine, which focuses on tailoring healthcare based on genetic profiles. As healthcare providers and patients recognize the potential benefits of genetic testing in identifying predispositions to certain diseases and personalizing treatment plans, demand has surged. The integration of genetic testing into routine healthcare practices is being encouraged by healthcare policies aimed at improving patient outcomes and reducing healthcare costs. There are ample opportunities to be explored in the U.S. market, particularly in the areas of direct-to-consumer testing and telemedicine.
As consumers seek more control over their health, companies offering genetic testing directly to the public are gaining popularity. The rise of telehealth services has also facilitated wider access to genetic counseling and testing, especially in rural areas where traditional healthcare access may be limited. Such innovations can aid in reaching underserved populations, thereby expanding the consumer base. Recent trends indicate a growing focus on multifactorial conditions and lifestyle diseases rather than just hereditary disorders. With an increased emphasis on preventative care, genetic testing is becoming pivotal in managing chronic illnesses.
Additionally, advancements in technology are enabling quicker, more accurate testing methods, leading to increased adoption by both healthcare providers and consumers. Moreover, regulatory frameworks in the U.S. are evolving to keep pace with these advancements, ensuring that genetic testing remains safe and effective for the population. The intersection of technology and personalized healthcare is indeed shaping the future of the genetic testing market within the United States.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
US Genetic Testing Market Drivers
Increasing Prevalence of Genetic Disorders
The rising occurrence of genetic disorders in the United States is a significant driver propelling the growth of the U.S. Genetic Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 33 babies are born with a genetic disorder in the U.S. This equates to roughly 120,000 infants annually. As awareness increases regarding the importance of identifying genetic risk factors early on, more patients are seeking genetic testing services.
Leading organizations such as the American College of Medical Genetics and Genomics have emphasized the importance of genetic testing in diagnosing and managing genetic conditions. These trends are expected to be supportive of market expansion, as healthcare providers increasingly recommend testing as part of routine healthcare for expectant parents and patients with hereditary disease risk.
Advancements in Genetic Testing Technologies
Technological advancements in genetic testing methods are fostering growth within the U.S. Genetic Testing Market Industry. Innovations like next-generation sequencing (NGS) have dramatically reduced the cost and turnaround time for genetic tests. The U.S. Food and Drug Administration (FDA) has also approved numerous NGS-based tests, which further validate and support the credibility of these diagnostics. The improvement in accuracy and reduction in costs make genetic testing more accessible to consumers, resulting in increased adoption.
Companies like Illumina and Thermo Fisher Scientific have played a crucial role in advancing these technologies in the U.S., which contributes to a market poised for rapid expansion.
Growing Awareness and Acceptance of Personalized Medicine
The societal shift towards personalized medicine is another key driver of the U.S. Genetic Testing Market Industry. The National Institutes of Health (NIH) reports a rise in the focus on precision health, where treatments and preventive measures are tailored to individuals based on their genetic makeup. This movement is supported by various healthcare bodies, which advocate for the incorporation of genetic testing into standard care practices. As healthcare professionals increasingly recognize the merits of tailored treatments that can improve patient outcomes, the demand for genetic testing is expected to grow significantly.
The integration of genetics into oncology and chronic disease management is further propelled by organizations like the American Society of Clinical Oncology, which highlights the need for genetic insights in treatment planning.
US Genetic Testing Market Segment Insights
Genetic Testing Market Type Insights
The U.S. Genetic Testing Market reflects a robust segmentation by 'Type,' showcasing an array of testing methodologies essential for advancing personalized medicine and improving patient outcomes. Among these, Molecular Genetic Tests, often referred to as DNA Tests, play a pivotal role in diagnosing genetic conditions and guiding treatment plans, underscoring their significance in the overall landscape of genetic testing. This category is gaining traction due to advancements in sequencing technologies and the growing awareness of genetic predispositions to various diseases, which is increasingly relevant in the U.S. healthcare framework. Chromosomal Genetic Tests encompass a broad array of tests targeted at identifying chromosomal abnormalities, and they serve as a crucial tool for prenatal diagnosis and cancer genomics, emphasizing the importance of early detection in enhancing treatment effectiveness and patient survival rates.
Biochemical Genetic Tests contribute uniquely by assessing the functional aspects of proteins in an individual's metabolism, making them indispensable in diagnosing metabolic disorders that manifest in childhood, thereby aligning with the U.S. priorities in neonatal screening and public health interventions. The "Others" category encompasses various innovative tests that cater to niche applications, offering solutions that may not fit into the conventional categories and reflecting the ongoing evolution and customization of genetic testing capabilities.
The recognition of genetic testing as a vital part of the modern healthcare ecosystem is evident as more healthcare providers integrate these tests into routine practice. Demand for personalized medicine continues to shape market growth, with an emphasis on tailored treatments based on genetic insights. The increasing prevalence of genetic disorders, combined with the growth in consumer interest inproactive health management, drives innovation and adoption across all types of genetic tests. However, the market faces challenges, including ethical considerations around genetic privacy, the need for regulatory clarity, and the complexities of genetic data interpretation. Despite these challenges, opportunities abound, particularly as technological advancements improve test accuracy and reduce costs, making genetic testing more accessible to a broader population. As a result, the U.S. Genetic Testing Market is poised for substantial growth, reflecting the ongoing integration of genetic insights into healthcare and the vital role of the various testing types in this evolution.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Genetic Testing Market Type Insights
The U.S. Genetic Testing Market is becoming increasingly vital in the healthcare landscape, encompassing various types that cater to different needs. The segment of Prescribed Genetic Testing is particularly significant as it contributes to personalized medicine, allowing healthcare providers to tailor treatments based on an individual’s genetic predisposition to certain conditions. This type of testing aids in early diagnosis and optimal patient management, which is becoming a cornerstone in improving healthcare outcomes across the United States.
On the other hand, Direct-to-Consumer Genetic Testing is rapidly gaining popularity, driven by increasing consumer interest in personal health and ancestry insights. This segment empowers individuals to take proactive steps in understanding their genetic makeup, leading to informed lifestyle choices. Increasing acceptance among consumers and advancements in technology are propelling both types of testing forward, allowing for seamless integration into everyday health management. The diversification within the U.S. Genetic Testing Market underscores the growing demand for these services, revealing an evolving landscape that reflects broader trends in personalized medicine and consumer health engagement.
Genetic Testing Market Application Insights
The U.S. Genetic Testing Market is experiencing significant growth, particularly within the Application segment, which is pivotal in both clinical and personal health contexts. Reproductive Health plays a crucial role, significantly impacting family planning and enhancing pregnancy outcomes through early screenings for genetic disorders. Cancer Screening incorporates genetic testing as a vital tool for the early detection and prevention of hereditary cancers, allowing individuals to make informed healthcare decisions. Ancestry testing has gained popularity, with many individuals seeking to understand their genetic heritage and lineage, fostering a broader interest in genetic connections.
Meanwhile, Predictive and Pre-Symptomatic Testing serves as an essential avenue for assessing genetic risks for various conditions, empowering individuals with knowledge about their potential health challenges. This diverse segmentation of the U.S. Genetic Testing Market reflects the varying needs and preferences of the population, emphasizing the importance of personalized healthcare. Each segment not only contributes to the overall market dynamics but also addresses critical health concerns, providing unique opportunities for innovation and advancements in genetic technologies.
With the ongoing demand for personalized medicine, the Application segment is positioned to play a significant role in shaping the future of healthcare in the U.S.
US Genetic Testing Market Key Players and Competitive Insights
The U.S. Genetic Testing Market has seen significant growth and development in recent years, propelled by advances in technology, increasing awareness of genetic disorders, and the rising demand for personalized medicine. This market is characterized by a competitive landscape with numerous players vying for market share. Companies in this sector are leveraging innovation in genomic research, enhancing their service offerings, and improving testing accuracy to capture the interest of healthcare providers and consumers alike. The ongoing evolution of regulations, along with a shift towards preventive healthcare, has opened new avenues for growth while presenting challenges related to data privacy and ethical considerations. As a result, the competitive insights of the U.S. Genetic Testing Market highlight not just the strengths of established companies but also the agility of new entrants, making for a dynamic industry environment.
LabCorp holds a prominent position in the U.S. Genetic Testing Market, capitalizing on its vast network of laboratories and established reputation within the healthcare community. The company’s extensive range of genetic tests, encompassing carrier screening, pharmacogenomics, and oncology-focused assessments, showcases its commitment to personalized medicine and patient care. LabCorp's strengths lie in its comprehensive testing services, efficient turnaround times, and broad accessibility for healthcare providers and patients nationwide. Additionally, the company continuously invests in technological advancements and partnerships that enhance its testing capabilities. This strategic approach has enabled LabCorp to maintain a significant market presence while meeting the growing demand for genetic testing services across various medical fields.
Exact Sciences has emerged as a leader in the U.S. Genetic Testing Market, particularly with its focus on early cancer detection, specifically colorectal cancer screening. The company's flagship product, a non-invasive stool DNA test, has garnered attention for its accuracy and convenience. Exact Sciences emphasizes innovation through research and development, which positions the company favorably amid competitive pressures. Its strategic mergers and acquisitions have expanded its capabilities, enabling the integration of advanced technologies and diagnostic expertise. Through collaborations with healthcare providers and ongoing marketing efforts, Exact Sciences actively promotes awareness of its testing services. The company's strengths include a specialized focus on cancer and genetic screening, robust market positioning, and an unwavering commitment to enhancing patient outcomes, thus solidifying its presence in the evolving landscape of genetic testing in the U.S.
Key Companies in the US Genetic Testing Market Include
US Genetic Testing Market Industry Developments
The U.S. Genetic Testing Market has experienced significant developments recently, particularly with innovations enhancing precision medicine. In August 2023, LabCorp announced a partnership with Illumina to integrate advanced sequencing technologies, aiming to improve the speed of genetic testing. Additionally, in September 2023, Invitae completed the acquisition of the oncology-focused Strata Oncology, expanding their genomic testing capabilities. Furthermore, Color Genomics recently introduced a new hereditary cancer test that targets high-risk populations, reflecting an increasing trend toward personalized healthcare solutions.
Market growth is evident, with companies like Exact Sciences and Myriad Genetics reporting increased revenue attributed to surging demand for genetic insights. The overall market valuation saw a substantial boost, driven by heightened awareness around genetic testing's role in disease prevention and management. Over the past few years, from 2021 through 2023, there has been a marked increase in regulatory approvals for genetic tests, enhancing market dynamics. The growing emphasis on preventive healthcare in the U.S. further fuels this sector, paving the way for more innovative testing solutions and strategic partnerships among leading firms like Quest Diagnostics and 23andMe.
Genetic Testing Market Segmentation Insights
| Report Attribute/Metric | Details |
| Market Size 2023 | 2.74(USD Billion) |
| Market Size 2025 | 3.68(USD Billion) |
| Market Size 2035 | 16.25(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 14.456% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | LabCorp, Exact Sciences, Natera, Color Genomics, Myriad Genetics, Quest Diagnostics, 23andMe, Fulgent Genetics, Genomic Health, Ginkgo Bioworks, Thermo Fisher Scientific, Illumina, Invitae, Strata Oncology |
| Segments Covered | Type, Type, Application |
| Key Market Opportunities | Increased demand for personalized medicine, Growing interest in ancestry testing, Expansion of direct-to-consumer testing, Advancements in genomic technologies, Rising awareness of hereditary diseases |
| Key Market Dynamics | increasing demand for personalized medicine, advancements in genomic technologies, growing awareness of hereditary diseases, favorable reimbursement policies, rising number of genetic disorders |
| Countries Covered | US |
Frequently Asked Questions (FAQ) :
The U.S. Genetic Testing Market was expected to be valued at 3.68 billion USD in 2024.
The market is projected to reach 16.25 billion USD by 2035.
The U.S. Genetic Testing Market is expected to grow at a CAGR of 14.456% from 2025 to 2035.
The Molecular Genetic Tests/DNA Tests segment is valued at 1.5 billion USD in 2024.
The Chromosomal Genetic Tests segment is projected to be valued at 4.6 billion USD by 2035.
Key players include LabCorp, Exact Sciences, Natera, Color Genomics, and Myriad Genetics, among others.
Biochemical Genetic Tests are expected to be valued at 0.8 billion USD in 2024.
The Other category is projected to grow to 1.15 billion USD by 2035.
Increasing awareness and demand for personalized medicine are key growth drivers for the market.
The market faces challenges such as regulatory hurdles and concerns over data privacy.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager
He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
